

Disclosure of the total number of voting rights and shares as of March 31, 2024

Paris, France, April 5, 2024 – 6:00 pm CEST - ACTICOR BIOTECH (FR00140050J5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of March 31, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

- Listing Place: Euronext Growth Paris
- ISIN Code : FR00140050J5
- Web site: acticor-biotech.com

Date	Number of shares making up the share capital	Theoretical number of voting rights ⁽¹⁾	Number of voting rights excluding shares stripped of voting rights ⁽²⁾
March 31, 2024	15.755.227	15.755.227	15.686.422

- (1) In accordance with Article 223-111 of the AMF's General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
- (2) The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the *Lancet Neurology* ([link to the publication](#)), confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. These results were confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence (Brainomix, UK). This independent analysis confirmed the reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab. The efficacy of glenzocimab is now being analyzed in an international Phase 2/3 study, ACTISAVE, with clinical results expected in Q2 2024.

In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 – ALACT).

For more information, visit: www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

NewCap

Mathilde BOHIN

Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95

NewCap

Arthur ROUILLÉ

Media Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 00 15